This year marks a major milestone for LIPOSORBER® as we celebrate 30 years of innovation, partnership, and commitment to advancing patient care. While we officially recognized this anniversary in June, the celebration continues throughout the summer as our Sales and Clinical Support Team (CST) members have been traveling across the country to connect with physicians,
A legacy of innovation, collaboration, and patient impact In June 1996, Liposorber® was first approved for use in the United States, marking the beginning of a new chapter in the treatment of complex lipid disorders and beyond. Thirty years later, that moment has grown into a legacy defined not only by clinical innovation, but by
When Aubree was just two weeks old, her family noticed something unusual – small bumps on her skin around her ankles and her wrists. At first, their concerns were dismissed as a skin care issue. But as the symptoms persisted, Aubree’s mother trusted her instincts and continued advocating for answers. By age two and a
In March 2026, the American College of Cardiology (ACC), American Heart Association (AHA), and partnering societies released updated U.S. dyslipidemia guidelines—marking a pivotal shift in how inherited cholesterol disorders are identified and managed. These new recommendations place strong emphasis on earlier detection, greater awareness of genetic risk, and more intensive treatment for patients at the
March is National Kidney Month, a time dedicated to raising awareness about kidney disease, early intervention, and the importance of personalized care. For people living with nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS), and for the clinicians who treat them, this month is also an opportunity to acknowledge a difficult reality: standard therapies may
When Avery was just six years old, her parents scheduled what they assumed would be a routine lipid screening. They knew high LDL cholesterol ran in the family, but nothing prepared them for the results that followed. Avery’s cholesterol levels returned at over 800 mg/dL, and a repeat test came back even higher. Further evaluation at a major
Effective October 2025, ICD-10-CM code E78.01 (Familial hypercholesterolemia) has been deleted and replaced with new, more specific codes. New Codes: What You Need to Know: Why This Matters: Action Steps for Providers: This update is part of the annual ICD-10-CM guidelines and aims to improve the accuracy of patient diagnosis, billing, and research data. Please
We’re excited to share two new resources designed just for you and your patients: “What to Expect When Starting Liposorber Treatment” – for adults and pediatrics. These short, patient-friendly videos walk through the therapy experience, step-by-step. Whether you’re onboarding a new patient or reinforcing long-term adherence, this video helps patients feel informed, confident, and supported. It provides guidance for
Peripheral Arterial Disease Associated with Elevated Lipoprotein(a): A Review of the Evidence and Treatment ApproachesCurrent Opinion in Lipidology, May 21, 2025Bhatia, Harpreet S.a; Dalal, Sonarb; Ross, Elsiec Why This Matters to Your Practice: This comprehensive review consolidates clinical evidence linking elevated Lp(a) to the onset, severity, and outcomes of PAD. Highlights include: Review Topics Include: Among
At UCHealth University of Colorado Hospital, our LIPOSORBER (Lipid Apheresis) treatment is available, making it the only facility in Colorado and the surrounding region offering this potentially life-saving procedure. According to a recent American Heart Association study, lipid apheresis is a “valuable but underused” therapy for patients with severe cholesterol disorders such as familial hypercholesterolemia
